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Decades of research on the use of micronutrient supple-
ments for cancer prevention have yielded inconsistent and
disappointing results. Here I reflect upon the limitations
of past research, and develop a framework for how to
move from basic biological and epidemiological research
to large, randomized cancer prevention trials. There are
many biologically rational hypotheses supporting effects of
micronutrient supplements for cancer prevention, with
thousands of supportive studies in in vitro and animal
models. But careful evaluation of much of this research
shows it irrelevant to human nutrition: agents tested are in
concentrations and forms that are never seen in vivo.
Small clinical studies often have no control groups, use
uninformative endpoints, or have obvious design or
analysis flaws. Epidemiological studies are challenging
because they can rarely capture biological complexity:
associations may differ by genetic characteristics or envir-
onmental exposures (e.g., smoking), and cancers with
diverse phenotypes are grouped by anatomic site. Further-
more, because supplement use is associated with many
other health-related behaviors and most supplement users
take multiple supplements, statistical methods cannot
reliably disentangle these highly inter-correlated factors.
Studies based on blood-based biomarkers of micronutrient
intake can be misleading, either because the biomarker is
an acute phase reactant (Se, a-tocopherol) or the biomar-
ker is not a valid measure of micronutrient status (Zn).
Randomized clinical trials have a high likelihood of yield-
ing null results, because often the optimal dose and
formulation of the agent are unknown, adherence is poor,
study duration is too short, or the outcome is misspecified.
Furthermore, many studies have found that micronutrient
supplementation increases cancer risk, suggesting the high
dose micronutrient supplementation can lead to subacute
toxicity. The challenge to biomedical research is to use in
vitro and animal experimental models that are relevant to
human nutrition, design and execute small clinical studies
with the same rigor required for pharmaceutical research,
and use micronutrient biomarkers that validly reflect
nutritional status. Clinical trials should more ahead only
when the biology is well-understood, the population likely
to benefit can be identified, and the funding is sufficient to
support programs to promote treatment adherence and
the collection and banking of biological specimens at
randomization and at multiple times post-randomization.
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